It's high time to become alert - A Totally drug resistant T.
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Sachit Sogani
It's high time to become alert - A Totally drug resistant T.B (TDR-TB) found in INDIA !!!!!

Physicians in India have identified a form of incurable tuberculosis there, raising further concerns over increasing drug resistance to the disease. Although reports call this latest form a “new entity”, researchers suggest that it is instead another development in a long-standing problem.

The discovery makes India the third country in which a completely drug-resistant form of the disease has emerged, Mohammed Shamim Sheikh, who suffers from 'total drug-resistant tuberculosis' lives in the outskirts of Mumbai, India. TDR -TB has already been documented in Italy in 2007 and Iran in 2009.
An untreatable form of tuberculosis has been found in India.
However, data on the disease, dubbed totally drug-resistant tuberculosis (TDR-TB), are sparse, and official accounts may not provide an adequate indication of its prevalence. Giovanni Migliori, director of the World Health Organization (WHO) Collaborating Centre for Tuberculosis and Lung Diseases in Tradate, Italy, suggests that TDR-TB is a deadlier iteration of the highly resistant forms of TB that have been increasingly reported over the past decade. “Totally resistant TB is not new at all,” he says.
Since the 1960s, two drugs — isoniazid and rifampicin — have been the standard TB treatment. Although episodes of resistance cropped up periodically, during the 1990s the incidence of multiple drug resistance grew significantly, leading researchers in 2006 to refer to it as extensively drug-resistant tuberculosis (XDR-TB). Surveillance data from the WHO indicate that XDR-TB is present in at least in 58 countries, with an estimated 25,000 cases occurring each year.
Epidemiologist Carole Mitnick of Harvard Medical School in Boston, Massachusetts, agrees that TDR-TB is not new, and points to the history of XDR-TB. “When XDR-TB was first named, it was a phenomenon that had existed but hadn’t gotten much attention before. TB in general doesn’t receive a lot of attention,” she says.

Inadequate care -
Global Fund halts new funding until 2014
WHO. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. (2010)
Global Alliance for TB Drug Development. 2009 report on Tuberculosis research funding trends, 2005-2009. (2009).
Part of the increase in drug resistance is related to complications that arise in treating patients who are also infected with HIV — 13% of TB cases, according to the WHO. However, the greatest part of the problem results from the management of the disease.

Although the WHO describes TB as a “disease of poverty”, drug-resistant varieties might best be understood as resulting from poor treatment. According to a 2011 WHO report, fewer than 5% of newly diagnosed or previously treated patients are tested for drug resistance. And it is estimated that just 16% of patients with drug-resistant TB are receiving appropriate treatment.

“The cases are a story of mismanagement,” says Migliori. “Resistance is man-made, caused by exposure to the wrong treatment, the wrong regimen, the wrong treatment duration.”
In the management of TB, many factors affect whether the disease is cured or becomes resistant to treatment. Drug misuse or mismanagement can result if a patient does not follow a full course of treatment, or if the correct drugs are not available or patients with undiagnosed resistant TB receive inappropriate therapies.

Part of the problem also relates to TB testing. The WHO recommends sputum smear microscopy, a test developed more than one hundred years ago, as the standard diagnosis. Although inexpensive, this method is prone to false negatives, does not provide information on drug susceptibility, and test results can take several weeks — a large window of time for a patient to potentially receive the wrong drugs or transmit the infection. However in 2010, the WHO approved a new rapid and fully automated test, known as Xpert, which assesses resistance to the first-line drug rifampicin. As of July 2011, 26 countries are using Xpert and 145 are eligible to purchase kits at a reduced price.


“The pharmaceutical industry had scant interest in TB for decades,” says Richard Chaisson, director of the Center for TB Research at the Johns Hopkins School of Public Health in Baltimore, Maryland. “The industry pretty much concluded it wasn’t an attractive market, there was not enough potential profit.”


Dr. B●●●l D●●●i and 24 others like this
Like
Comment
Share
S●●●●t S●●●●i
S●●●●t S●●●●i General Medicine
To detect cases of latent infection, the government has launched a door-to-door screening campaign for tuberculosis (TB). The Union health ministry has started a campaign to find patients before they develop full-blown TB and put them on preventive treatment. The campaign has been launched in five Indian states, the official launch had been done in January 2017. The states being covered in first phase - Kerala, Bihar, Maharashtra, Himachal Pradesh and Sikkim. Mostly new agendas are being made other than this and plus the DOTS programme has been renewed this year to improve the efficacy of treatment !! ... Read more
May 25, 2017Like
Dr. R●●●●●●a N●●h
Dr. R●●●●●●a N●●h General Medicine
And what is the status of Bedaquiline in TDR cases ?
May 25, 2017Like1
S●●●●t S●●●●i
S●●●●t S●●●●i General Medicine
Actually there is no accurate data on that, I just know it is a strong drug to combat MDR - TB !!
May 25, 2017Like